Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

Vertex is presented as the preferred 2026 investment over Amgen, supported by FY2025 revenue growth of 9.6% to $12.1B, a 32.7% net margin, low 0.2x debt-to-equity, and a 2.9x current ratio. Vertex's Casgevy revenue more than doubled year over year, management raised its full-year outlook, and expansion into pain treatment and a pending acquisition could diversify its disease exposure. Amgen generated larger FY2025 revenue of $36.7B and $8.1B of free cash flow, but faces elevated leverage at 6.3x debt-to-equity, biosimilar competition, and Medicare pricing risk; it trades at 16.4x forward P/E versus Vertex's 41.5x.

Analysis

The key investable distinction is not headline growth but durability of incremental earnings. VRTX's premium multiple assumes cystic-fibrosis cash flows can fund credible diversification; therefore, each non-CF revenue update must clear a high bar. CASGEVY uptake is strategically important but unlikely to be valuation-material near term given treatment-center capacity, conditioning requirements, payer authorization and manufacturing throughput; investors should separate patient starts from recognized revenue and gross-margin contribution.

AMGN's lower multiple embeds patent-loss and leverage concerns, but it also creates asymmetric upside if newer assets offset erosion faster than consensus expects. The more immediate earnings swing factor is net price realization and biosimilar share loss rather than wholesaler concentration: MCK, COR and CAH have limited direct upside because distribution economics are predominantly fee-based, while pressure on manufacturer list-to-net pricing can reduce AMGN revenue without meaningfully impairing distributor volumes.

Over 1-3 months, VRTX is vulnerable to a de-rating if pipeline setbacks or a slower-than-expected launch cadence expose its reliance on CF, especially at a valuation roughly 2.5x AMGN's forward earnings multiple. Over 6-18 months, VRTX can sustain its premium only if non-CF businesses demonstrate repeatable commercial execution; AMGN can rerate if post-biosimilar portfolio growth supports stable free cash flow and debt reduction. The contrarian view is that balance-sheet quality is already fully rewarded in VRTX, whereas AMGN's dividend-supported cash flow may offer better downside protection in a risk-off healthcare rotation.

Key Decisions for Investors

• Maintain a modest long VRTX only on pullbacks or after quarterly evidence of accelerating non-CF revenue; use a 6-12 month horizon. Require commercial metrics beyond prescriptions—patient starts, reimbursement conversion and gross-margin trajectory—as confirmation. Exit/reduce on lowered CF net-revenue guidance or another material pipeline discontinuation; premium-multiple downside could be 20%+.
• Initiate a 6-12 month relative-value pair: long AMGN / short VRTX, sized beta-neutral, for investors seeking valuation mean reversion. The pair benefits if AMGN's portfolio offsets biosimilar erosion while VRTX's diversification timeline slips; target 10-15% relative return. Falsify if VRTX non-CF revenue reaches clearly material scale faster than consensus or AMGN guides to accelerating core-franchise declines.
• Do not add CRSP solely on CASGEVY commentary. Treat quarterly treatment-center activation, manufacturing capacity, patient throughput and CRSP's economics after the Vertex profit split as prerequisite data; until then, it remains a high-volatility pipeline exposure rather than a clean read-through on VRTX.
• Monitor AMGN net price realization, biosimilar volume/share trends and free-cash-flow-to-debt reduction at each earnings release. A meaningful guidance cut or failure to preserve cash flow would remove the valuation cushion and argues against the AMGN leg.